In an 83‑year‑old patient currently using Kenalog (triamcinolone acetonide) twice weekly and wishing to continue only that medication, what is the appropriate dosing regimen for an exacerbation of lichen sclerosus?

Dosing Kenalog for Lichen Sclerosus Exacerbation

For an exacerbation of lichen sclerosus in this 83-year-old patient currently using Kenalog twice weekly, switch to clobetasol propionate 0.05% ointment once daily until symptoms resolve, then return to maintenance therapy—this is the evidence-based standard of care. However, if the patient absolutely refuses to change medications, intralesional triamcinolone 10–20 mg can be considered for hyperkeratotic areas resistant to topical therapy 1.

The Evidence-Based Problem with Current Management

The British Association of Dermatologists 2018 guidelines are unequivocal: clobetasol propionate 0.05% is the first-line treatment for lichen sclerosus, not triamcinolone 1. The patient's current twice-weekly Kenalog regimen is suboptimal for several critical reasons:

• Triamcinolone is a mid-potency steroid, while LS requires ultrapotent topical steroids (clobetasol) to prevent scarring and reduce malignancy risk
• The guidelines recommend clobetasol for both initial treatment and ongoing active disease 1
• Quality of life, sexual function restoration, and cancer risk reduction are the critical outcomes in LS management 1—outcomes best achieved with ultrapotent steroids

If Patient Insists on Kenalog Only

For Exacerbation Management:

Intralesional triamcinolone 10–20 mg is the only guideline-supported use of triamcinolone in LS, specifically for:

• Topical steroid-resistant hyperkeratotic areas
• Must exclude malignancy/intraepithelial neoplasia by biopsy first 1

Per FDA labeling, intralesional dosing varies by lesion, with injections potentially repeated at weekly or less frequent intervals 2. The 1999 study showed intralesional triamcinolone hexacetonide reduced symptom severity in LS patients who couldn't use topical treatments 3.

Critical Caveats:

1. This is NOT standard of care—it's a second-line option for resistant disease only
2. Biopsy is mandatory before intralesional injection to rule out malignancy 1
3. The patient's current topical twice-weekly regimen has no guideline support for LS
4. Risk of tissue atrophy with intralesional injections, particularly with repeated use 2

The Safer Alternative Approach

Strongly counsel the patient to switch to clobetasol 0.05% ointment with this exacerbation regimen:

• Once daily until symptoms resolve (typically 1–3 months for flares)
• Then taper to alternate days, then twice weekly for maintenance 1
• This prevents scarring and architectural changes that become irreversible

The 2011 study showed topical triamcinolone reduced LS symptoms 4, but this was comparing it to nothing—not to the gold standard clobetasol. The guidelines explicitly state ultrapotent steroids are needed 1.

Why This Matters for an 83-Year-Old

• Untreated or undertreated LS increases vulvar/penile cancer risk—a critical outcome at any age 1
• Architectural changes and scarring become permanent without adequate treatment
• Sexual function and urinary symptoms worsen with disease progression
• Mid-potency steroids like triamcinolone may control symptoms temporarily but don't prevent long-term complications

Bottom Line Algorithm

1. First choice: Switch to clobetasol 0.05% once daily for exacerbation
2. If patient refuses: Refer to specialist for biopsy to exclude malignancy, then consider intralesional triamcinolone 10–20 mg for resistant hyperkeratotic areas only 1
3. Document patient refusal of standard therapy and cancer risk counseling
4. Follow closely for disease progression and architectural changes

The patient's preference for Kenalog alone puts them at risk for inadequate disease control and its serious sequelae. This warrants frank discussion about the limitations of their preferred treatment and the superior outcomes with guideline-concordant therapy.